CYP2B6 and non-Hodgkin lymphoma: Induction of CYP2B6 by a selective activator (e.g., CITCO) facilitates the bioactivation of CPA to 4-OH-CPA and improves the therapeutic outcome of CHOP (cyclophosphamide–doxorubicin–vincristine–prednisone) chemotherapy against non-Hodgkin lymphoma (Shu et al., 2017).